COMPUGEN (Israel) Profile

Performance

Odds of Distress

54%54%
Analyze Filter    Check how we calculate scores
Equity ratings for COMPUGEN are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting September 7, 2019 and ending today December 6, 2019. Click here to learn more.
COMPUGEN cannot be verified against its exchange. It appears that COMPUGEN is not available for investing at the moment. Please verify the symbol is currently traded on Tel Aviv Stock Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refesh

COMPUGEN Profile

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 89 people.. The public information regarding COMPUGEN's current market price is not available at this time.
NameCOMPUGEN
CEOAnat CohenDayagView All
Macroaxis Advice
InstrumentIsrael Stock View All
RegionMiddle East
Business AddressBuilding D
Foreign Associate  USA
ExchangeTel Aviv Stock Exchange
CIK Number0001119774
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.cgen.com
Phone972 3 765 8585
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterSeptember 30, 2019
Last Fiscal Year EndDecember 31, 2018
COMPUGEN (CGEN) is traded on Tel Aviv Stock Exchange in Israel and employs 89 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 1.2 B. COMPUGEN operates under Healthcare sector and is part of Biotechnology industry. The entity has 62.39 M outstanding shares. COMPUGEN has accumulated about 47.64 M in cash with (21.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.73.
Check COMPUGEN Probability Of Bankruptcy

COMPUGEN Income Statement Over Time

Net Income    Revenues    

COMPUGEN Key Fundamentals

COMPUGEN Against Markets

COMPUGEN cannot be verified against its exchange. It appears that COMPUGEN is not available for investing at the moment. Please verify the symbol is currently traded on Tel Aviv Stock Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refesh

Try Other Stock Suggestions

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 89 people.. The public information regarding COMPUGEN's current market price is not available at this time.
NameCOMPUGEN
CEOAnat CohenDayagView All
Macroaxis Advice
InstrumentIsrael Stock View All
RegionMiddle East
Business AddressBuilding D
Foreign Associate  USA
ExchangeTel Aviv Stock Exchange
CIK Number0001119774
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.cgen.com
Phone972 3 765 8585
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterSeptember 30, 2019
Last Fiscal Year EndDecember 31, 2018

COMPUGEN Corporate Directors

Joshua Shemer Independent External Director
Michal Preminger Director
Dov Hershberg Director
Check also Trending Equities. Please also try Equity Search module to search for activelly-traded equities including funds and etfs from over 30 global markets.
Search macroaxis.com